menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
EllenVigdorth
Outbreak: Ebola, Africa, Dengue Fever, Japan, Chikungunya, Jamaica. We’ve all read the headlines and seen the devastating damage that these “tropical diseases” can wreak on a population. And we’ve also seen how these once remote diseases are creeping across the globe as the bugs know no borders.   Ebola, one of the most terrifying diseases, demonstrated its remarkable ability to spread across countries this year. The outbreak that began in Guinea managed to jump borders into Liberia, Sierra Leone and Nigeria, causing many to wonder whether or when it might spread beyond Africa. Several airlines cut flights to some of the highest risk countries for fear the disease could be transported worldwide. WHO and other health experts expressed concerns that 20,000 people may become...
Read More
PatrickJordan
There was a great Harvard Business Review article from 1960 called " Marketing Myopia " in which Theodore Levitt said every industry was once a growth industry. Staying there required answering the question of what business the industry was really in, which is deceptively obvious. He talked about the demise of railroad companies at the turn of the 20th century when — contrary to expectation — passenger and freight demand grew, not shrunk. He claimed that railroad companies were "railroad oriented instead of transportation oriented; they were product oriented instead of customer oriented." That failure of recognition allowed other industries like auto, trucking, and aviation enter the railroad market and address the broader problem of transportation.  One doesn't need to look too far...
Read More
PaulSutton
There was a time not so long ago when it seemed like the world of biopharma was a little less complex. On the surface, the goal was to increase prescription rates and adherence to medicines, which would lead to better patient outcomes. This would in turn support ongoing availability and reimbursement of a drug.  But what has changed is the demand by stakeholders for robust evidence of how efforts by biopharmaceutical companies can impact and support the achievement of those outcomes in the real world. Biopharma companies need to provide decision-makers with complete confidence that their product will have the expected impact on stratified patient populations. The answer to this question lies in real-world data, and one of the most effective ways of securing this data is through an...
Read More
EricaCaveney
Type 2 diabetes patients regularly suffer from a variety of comorbidities, including retinal disease, cardiovascular disorders, obesity, hypertension, dyslipidemia, fatty liver disease, microvascular and macrovascular complications, and a number of cancers – just to name a few. These comorbidities add complexity to their treatment regime and lessen their quality of life.  This is a serious medical dilemma for patients, and it should be a driver of research for the biopharmaceutical community.  The diabetes treatment marketplace is already crowded with competitors. Many classes of agents offer five or more options, with what differentiates them from each other being fairly nuanced. This is making it harder for biopharma companies to bring new products to market – or to get them...
Read More
BrianKelly
Healthcare stakeholders agree -- at least in theory -- that a systems-thinking approach to healthcare is necessary and beneficial for the entire industry. Our research shows that almost three quarters of all industry stakeholders surveyed believe that cross-industry collaborations bring opportunity rather than challenge to their organizations.  But their actual transition to a more collaborative system-oriented model is slow, and laden with obstacles. One of the biggest challenges they face is around access to data. The lack of standardization and investment into integration models is preventing all healthcare players from making informed decisions in the timeliest manner. This lack of data integration is an albatross for the industry, adding unnecessary expense, risk and...
Read More
LynnHughes
Alzheimer’s Disease is becoming a global healthcare crisis. By 2050, the number of people exhibiting dementia worldwide is forecast to rise to 115.4 million , and roughly 43% of AD cases will require levels of care equivalent to that provided by nursing homes. In 2010, caring for dementia patients cost $604 billion worldwide, and the number will continue to grow as populations age. But a new global initiative , sponsored by the G7 and chaired by UK Prime Minister David Cameron, aims to turn those numbers around. This ground-breaking research program, developed by the European Prevention of Alzheimer's Disease Consortium (EPAD), plans to draw thousands of patients from across the European Union who at risk for early Alzheimer’s, and funnel them into an adaptive trial where multiple...
Read More
Kamali Chance
As the biosimilars marketplace matures, EU and US regulatory agencies are beginning to align around regulatory guidelines for development of biosimilars, which is beneficial for the entire industry.  Currently, there are few differences between regulatory guidelines from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Both regulatory agencies have similar requirements for sourcing of the reference product for analytical, non-clinical ( in vitro and/or in vivo ), as well as Phase I comparability studies. Both agencies require the reference product to be sourced from the country/region of interest – i.e., for a biosimilar product to be approved in the US, it has to be sourced from the US, even though the product may have the same name as the one...
Topics: Biosimilars; EMA; EU; FDA
Read More
Under the Influence of Payers
One question is asked by every stakeholder in every industry: who really wields the power and influence? It is also often swiftly followed up by a second query: why isn't it us?  In healthcare, finding the answer to those questions is inextricably linked to understanding value. The stakeholder most able to position themselves as defining value is the one who ultimately shapes which drugs are developed, commercialised and prescribed, and therefore ultimately whether or not patient needs are met. So in the complex local health economies we find ourselves working in, who is it that wields the most influence?  Tipping the balance towards payers   The climate is becoming increasingly complex following the changes to the NHS in 2013. There are now potentially as many different definitions...
Read More
John Doyle
In the context of assessing risk and benefit, one area that warrants further examination is comparative effectiveness research (CER). As private payers and quasi-governmental agencies in the U.S. rush to embrace CER, some insight can be gleaned from looking at how U.K payers perceive health technology assessments (HTA)— a different yet related tool to evaluate real-world effectiveness and risk profiles of products versus standardized therapy. In Quintiles’ recent survey of U.S. and U.K payers and other industry stakeholders, we found UK payers are less impressed by HTA than US payers are of CER on a number of different measures.  Less than a third of UK payers feel that HTA perform very or extremely well on improving patient outcomes, and less than a quarter feel that HTA do a good...
Read More
LynnHughes
By 2015, dementia caused by Alzheimer’s Disease (AD) will affect one in every 85 people worldwide. The financial and emotional impact of this condition is staggering to both patients and their families, and new treatments are desperately needed to help arrest this trend. If interventions were available to delay both disease onset and progression by just one year, there would be almost  9.2 million fewer cases of AD in 2050 .  Biopharmaceutical companies around the world are racing to develop therapies that will slow or even stop the progression of AD. But the lack of accessibility to trial participants is frustrating their progress.  Ideally, AD clinical research programs identify patients at an early stage of their disease in the hope of influencing its course using...
Read More